• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Caribou Biosciences Inc (NQ: CRBU )

    1.610 -0.010 (-0.60%)
    Streaming Delayed Price Updated: 9:31 AM EDT, Jun 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 27,032
    Open 1.620
    Bid (Size) 1.610 (1)
    Ask (Size) 1.620 (7)
    Prev. Close 1.620
    Today's Range 1.605 - 1.630
    52wk Range 1.600 - 8.590
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cracking The Code: Understanding Analyst Reviews For Caribou Biosciences
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga

    Performance

    YTD
    -71.09%
    -71.09%
    1 Month
    -46.14%
    -46.14%
    3 Month
    -68.55%
    -68.55%
    6 Month
    -72.75%
    -72.75%
    1 Year
    -60.63%
    -60.63%

    More News

    Read More
    Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    Expert Ratings For Caribou Biosciences
    Via Benzinga
    Attention Biotech Investors - Stocks To Watch
    Via Benzinga
    3 Underappreciated Stocks That Could 10x in 10 Years
    Via InvestorPlace
    CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    Caribou Biosciences to Participate in Upcoming Investor Conferences
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Points
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Gold Down Over 1%; ClearOne Shares Spike Higher
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Caribou Biosciences Stock Is Crashing Today
    Via The Motley Fool
    Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
    Via Talk Markets
    Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold
    Via The Motley Fool
    Caribou Biosciences to Participate in Upcoming Investor Conferences
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.